1
|
Zhao J, Zhang X, Du Y, Zhou L, Dong Z, Zhao J, Lu J. Allogenic mouse cell vaccine inhibits lung cancer progression by inhibiting angiogenesis. Hum Vaccin Immunother 2021; 17:35-50. [PMID: 32460680 DOI: 10.1080/21645515.2020.1759996] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Abstract
Aim: This research investigated the therapeutic effect of an allogeneic mouse brain microvascular endothelial cell vaccine on lung cancer and further elucidated its potential anti-angiogenic mechanism. Materials & methods: The immune effect of the allogeneic bEnd.3 vaccine and DC vaccine loaded with bEnd.3 antigen on the subcutaneous transplantation of Lewis lung cancer (LLC) was assessed by ELISA, the CCK test and the CTL killing test. The mechanism was preliminarily revealed by immunohistochemistry and immunoblot analysis. Results: This study revealed that tumor volume was decreased (p < .01) and the survival was prolonged significantly (p < .05) by the bEnd.3 vaccine in subcutaneous LLC transplantation in the vaccine prevention group. In contrast, both tumor volume in the serum therapeutic group and survival of bEnd.3 vaccine were not significantly different from those of the control group (p > .05). Importantly, tumor volume and survival of the T lymphocyte therapeutic group were decreased and prolonged (p < .05). In addition, both tumor volume and survival of DC vaccine loaded with bEnd.3 in the vaccine prevention group were decreased and prolonged significantly (p < .01). Furthermore, bEnd.3 vaccine and DC vaccine loaded with bEnd.3 both produced the activity of killing bEnd.3 target cells in vitro.The reason may induce the immune mice to produce anti-VEGFR-II, anti-endoglin and anti-integrin αν antibodies to have an anti-angiogenesis function. Conclusion: The allogeneic mouse bEnd.3 cell vaccine can block angiogenesis and prevent the development of lung cancer transplantation tumors.
Collapse
Affiliation(s)
- Jun Zhao
- Department of Oncology, Changzhi People's Hospital , Changzhi, China.,Department of Pathophysiology, College of Basic Medical Sciences, Zhengzhou University , Zhengzhou, China
| | - Xiaoling Zhang
- Department of Oncology, Changzhi People's Hospital , Changzhi, China
| | - Yunyi Du
- Department of Oncology, Changzhi People's Hospital , Changzhi, China
| | - Lurong Zhou
- Quality Control Department, Changzhi People's Hospital , Changzhi, China
| | - Ziming Dong
- Department of Pathophysiology, College of Basic Medical Sciences, Zhengzhou University , Zhengzhou, China.,Collaborative Innovation Center of Henan Province for Cancer Chemoprevention , Zhengzhou, China.,State Key Laboratory of Esophageal Cancer Prevention and Treatment, Zhengzhou University , Zhengzhou, China
| | - Jimin Zhao
- Department of Pathophysiology, College of Basic Medical Sciences, Zhengzhou University , Zhengzhou, China.,Collaborative Innovation Center of Henan Province for Cancer Chemoprevention , Zhengzhou, China.,State Key Laboratory of Esophageal Cancer Prevention and Treatment, Zhengzhou University , Zhengzhou, China
| | - Jing Lu
- Department of Pathophysiology, College of Basic Medical Sciences, Zhengzhou University , Zhengzhou, China.,Collaborative Innovation Center of Henan Province for Cancer Chemoprevention , Zhengzhou, China.,State Key Laboratory of Esophageal Cancer Prevention and Treatment, Zhengzhou University , Zhengzhou, China
| |
Collapse
|
2
|
Improved Antitumor Efficacy of Combined Vaccine Based on the Induced HUVECs and DC-CT26 Against Colorectal Carcinoma. Cells 2019; 8:cells8050494. [PMID: 31121964 PMCID: PMC6562839 DOI: 10.3390/cells8050494] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2019] [Revised: 05/20/2019] [Accepted: 05/21/2019] [Indexed: 12/24/2022] Open
Abstract
Angiogenesis is essential for the development, growth, and metastasis of solid tumors. Vaccination with viable human umbilical vein endothelial cells (HUVECs) has been used for antitumor angiogenesis. However, the limited immune response induced by HUVECs hinders their clinical application. In the present study, we found that HUVECs induced by a tumor microenvironment using the supernatant of murine CT26 colorectal cancer cells exerted a better antiangiogenic effect than HUVECs themselves. The inhibitory effect on tumor growth in the induced HUVEC group was significantly better than that of the HUVEC group, and the induced HUVEC group showed a strong inhibition in CD31-positive microvessel density in the tumor tissues. Moreover, the level of anti-induced HUVEC membrane protein antibody in mouse serum was profoundly higher in the induced HUVEC group than in the HUVEC group. Based on this, the antitumor effect of a vaccine with a combination of induced HUVECs and dendritic cell-loading CT26 antigen (DC-CT26) was evaluated. Notably, the microvessel density of tumor specimens was significantly lower in the combined vaccine group than in the control groups. Furthermore, the spleen index, the killing effect of cytotoxic T lymphocytes (CTLs), and the concentration of interferon-γ in the serum were enhanced in the combined vaccine group. Based on these results, the combined vaccine targeting both tumor angiogenesis and tumor cells may be an attractive and effective cancer immunotherapy strategy.
Collapse
|